GLP-1 Market
LLY $1288.30 ▲ +0.5% NVO $38.29 ▼ -1.0% PFE $29.45 ▼ -1.2% VKTX $25.36 ▲ +1.9% KLRA $13.42 ▲ +2.2% GPCR $21.48 ▼ -0.3% RHHBY $60.22 ▼ -0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MWN109 2

MWN109 2

Company
Shanghai Minwei Biotechnology Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 29, 2026

Find a Clinical Trial Near Me

See recruiting studies for MWN109 2 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07801820

    Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 240 participants Est. completion 2027-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07778693

    Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 760 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Completed NCT NCT07787728

    Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 40 participants Est. completion 2025-12-16 1 site Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Completed NCT NCT07791524

    Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 255 participants Est. completion 2026-07-09 1 site Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07791537

    Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 125 participants Est. completion 2026-11 1 site Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Completed NCT NCT07791654

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 120 participants Est. completion 2026-03-21 1 site Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07804797

    Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity

    Not yet reported Shanghai Minwei Biotechnology Co., Ltd 71 participants Est. completion 2026-09 1 site Stand-alone
    Other conditions: Overweight , Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.